Managing Comorbidities in Patients With Rheumatoid Arthritis

Slides:

Advertisements

Similar presentations

The Management of Comorbid Conditions in Patients with Rheumatoid Arthritis Collaborative Care.

Advertisements

Risk Factors for Rheumatoid Arthritis

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

PCSK9 Inhibitors Post-CVOTs

EULAR Study Group for Risk Factors for Rheumatoid Arthritis

Risk Factors for Rheumatoid Arthritis

Diagnosing Rheumatoid Arthritis Early

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Obesity and Dyslipidemia: How Would You Treat?

Statin Selection in Special Patient Populations: A Case Challenge

Introduction. Risk Communication With Patients: Your Guide to Resources and Recommendations.

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Obesity Management Today:

The Nurse View: Best Practices in Multiple Myeloma

Diabetes Increases Risk of CVD

Assessing the State of Statin Therapy

What Does the Primary Care Physician Need to Know About Chronic Hepatitis C?

An Update on PCSK9 Inhibitors

Precision Management of RA and Comorbidities

Time to Take Gout Seriously

Statins, HIV, and CVD.

A Pharmacist's Guide to PCSK9 Inhibitors:

Evaluating LDL-C Recommendations

Cardiovascular Comorbidities A Common Occurrence With COPD

The future of urate-lowering strategies for gout

Introduction. A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment.

Personalizing Statin Therapy in Patients With HIV

Overview. 5 Things You Need to Know About Statin Selection in Patients With HIV Infection.

Rheumatoid Arthritis 2015 Guidelines What's New? What's Different?

Improving Appropriate Access to PCSK9 Inhibitors

Statins and HIV:.

A PCP's Guide to Dyslipidemia

Debating the Issues in Rheumatoid Arthritis with the Experts: Early Treatment and Targets.

Guided by Objective Measures: Challenging Case Scenarios in Rheumatoid Arthritis.

Atrial Fibrillation.

Nat. Rev. Rheumatol. doi: /nrrheum

Comorbidities in RA and PsA

Statins, HIV, and CVD.

Goals. Weight Management Goals and Approaches in Patients With Type 2 Diabetes.

Residual CV Risk in Patients With Dyslipidemia and Stable CAD

SLE and Cardiovascular Risk

Case 1 Presentation Case 1 (cont) Assessment and Recommendations.

Viewpoints of Practicing Rheumatologists: Case Discussions in RA

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Интерпретация және зерттеу нәтижесін өңдеу

PPD status of CZP-treated patients with RA in the pooled RA safety database (N=4049) at baseline and TB incidence by INH treatment. †One patient who developed.

First-Line FCR: Effect of del(17p) on PFS and OS

Updates in RA, PsA, and Biosimilars

Tackling CV Risk in Type 2 Diabetes -- Gaps Between Guidelines and Clinical Practice?

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Lipid Updates From Spring 2019

An Update on PCSK9 Inhibitors

The severity of fatigue over 8 years of disease in early rheumatoid arthritis patients. The severity of fatigue over 8 years of disease in early rheumatoid.

Omega-3s vs Pure EPA in Clinical Practice

EULAR-defined characteristics describing arthralgia at risk for RA

Statin Selection in Patients With Pre-Diabetes: Case Considerations

The association between alcohol consumption and the severity of MRI-detected inflammation in hand and foot joints of (A) patients with RA and (B) asymptomatic.

Clinical response in patients with early and established RA at month 24. *p

Patients with RA on csDMARDs with and without GC, bDMARDs/tofacitinib with and without GC on the x axis. Patients with RA on csDMARDs with and without.

What's New in Oral Combination Therapy for Type 2 Diabetes?

The Study Group aims to:

Satisfaction with control of RA

EULAR Study Group for Risk Factors for Rheumatoid Arthritis

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Cardiovascular disease risk assessment capture rates in the NOCAR project, evaluated across diagnosis groups and participating centre. Cardiovascular disease.

Incidence rates of hospitalised infection per 100 person-years, standardised for age and sex, among patients with RA from five RA registries and one RA.

ACPA and RF titres in patients with early RA treated with abatacept+MTX compared with MTX alone. ACPA and RF titres in patients with early RA treated with.

Changes in non-classical (CD11b+CD14+CD163−CD16+) and classical (CD11b+CD14+CD163+CD16−) monocytes over time in patients with rheumatoid arthritis (RA)

Kaplan-Meier failure curves with development of RA stratified by depression exposure. Kaplan-Meier failure curves with development of RA stratified by.

Presentation transcript:

Managing Comorbidities in Patients With Rheumatoid Arthritis

Increased Risk for CVD

High 10‐Year Risk of CVD in Newly Diagnosed RA Patients A Population‐Based Cohort Study

Suboptimal CV Risk Management

Factors Associated With Increased CV Risk

CV Risk Assessment

2010 EULAR Recommendations, CV Risk

ASCVD Risk Calculator

Prescribing Statins Patients on the Cusp

Barriers to Reducing CV Risk

NJH Pre-Test Questionnaire

NJH RA/CVD Collaboration

NJH Resources for Patients

Weight Loss/Management

Challenges to Losing Weight

Discussion Lessons Learned

Abbreviations